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Background: Long-term survival outcomes of patients who undergo endoscopic 
management of non-invasive upper tract urothelial carcinoma remain uncertain. The 
longest mean follow-up period in previous studies was 6.1 years. This study reports the 
long-term outcomes of patients with upper tract urothelial carcinoma who underwent 
ureteroscopic ablation at a single institution over a 28-year period. 
Methods: We identified all patients who underwent ureteroscopic management of upper 
tract urothelial carcinoma as their primary treatment at our institution between January 
1991 and April 2011. Survival outcomes, including overall survival, cancer-specific 
survival, upper-tract recurrence-free survival, and renal unit survival, were estimated 
using Kaplan-Meier methodology. 
Results: A total of 15 patients underwent endoscopic management, with a mean age at 
diagnosis of 66 years. All patients underwent ureteroscopy, and biopsy-confirmed 
pathology was obtained. Median (range; mean) follow-up was 11.7 (2.3-20.9; 11.9) 
years. Upper tract recurrence occurred in 87% (n=13) of patients. Twenty percent (n=3) 
of patients proceeded to nephroureterectomy. The estimated cancer-specific survival 
rate was 93% at 5, 10, 15, and 20 years. Estimated overall survival rates were 86%, 80%, 
54%, and 20% at 5, 10, 15, and 20 years. Only 1 patient experienced cancer-specific 
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mortality. The estimated mean and median overall survival times were 14.5 and 16.6 
years, respectively. The estimated mean cancer-specific survival time was not reached.  
Conclusions: Although upper tract recurrence is common, endoscopic management of 
non-invasive upper tract urothelial carcinoma provides a 90% cancer-specific survival 
rate at 20 years in selected patients. 
 
Mini Abstract 
The long-term (mean, 11.9 years) survival outcomes of selected patients who underwent 
endoscopic management of upper tract urothelial cell carcinoma was excellent with 
90% cancer-specific survival rate at 20 years. 
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The standard treatment for upper tract urothelial carcinomas (UTUC) is radical 
nephroureterectomy with excision of the bladder cuff, due to reported durable outcomes 
and high recurrence rates experienced by patients with UTUC due to tumor 
aggressiveness [1-3]. However, interest in renal preservation and the local management 
of UTUC with ureteroscopy and laser ablation therapy has increased in recent years.  
Ureteroscopic management was historically limited to very select patients who have 
a solitary kidney, bilateral UTUC, end-stage chronic kidney disease, or comorbidities 
preventing radical surgery [4, 5]. Beyond such imperative reasons, the role of 
ureteroscopic management has recently extended to otherwise healthy patients with 
low-grade unifocal disease with a normal contralateral kidney. The recently updated 
European Association of Urology Guidelines indicate that conservative management of 
UTUC can be considered in patients with clinically low-risk cancer in elective 
situations [1]. 
Although ureteroscopic management is a recognized option for selected patients, 
information about long-term survival outcomes and risks has been based on the results 
of relatively small series, without long-term follow-up. To date, no institution has 
reported outcomes beyond a mean follow-up of 10 years; the longest mean follow-up 
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period has been 6.1 years (Table 1) [6-9]. 
Our institution has over 28 years of experience in minimally invasive management 
of UTUC, with excellent follow-up. Herein, we report on the natural history of UTUC 




2. Materials and Methods 
2.1.  Patients and procedures 
We retrospectively collected data from all UTUC patients who underwent ureteroscopic 
management at Okayama University Hospital between January 1991 and April 2011. All 
patients were followed up for >6 years, except for 2 who died within 6 years. 
Ureteroscopic management was selected based on imperative indications, which were 
defined as a solitary kidney, compromised renal function, or poor general condition 
(primary indications), or individual surgeon and patient preference (elective indications) 
for patients with low grade and low stage UTUC, with consent obtained from each 
patient. Before ureteroscopy, all patients considered possible candidates underwent 
computed tomography (CT), cystoscopy, and cytology of voided urine. Patients with 
positive urine cytology were encouraged to undergo nephroureterectomy, however, 3 
patients elected to undergo ureteroscopic management.  Clinical and pathological 
information was acquired from hospital medical records to assess outcomes. 
Pathological verification was obtained via ureteroscopic cold-cup biopsy. Tumor staging 
was based on the 2002 American Joint Committee of Cancer TNM classification, and 
tumors were graded according to the World Health Organization International Society of 
Urological Pathology consensus classification [10, 11]. This retrospective study 
complied with the standards of the Declaration of Helsinki and current ethical 
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guidelines, and was approved by the Okayama University Institutional Review Board 
(Approval number; 1906-014).  
The ureteroscopic procedures and techniques used at our institution for observation 
of the upper urinary tract have been described previously [12-14]. Briefly, the distal to 
middle portion of the ureter was inspected using a 6.9 Fr semi-rigid ureteroscope 
without a guide wire. An initial guide wire was then placed up to the middle ureter in 
order to avoid any inadvertent injury to the collecting system. The semi-rigid 
ureteroscope was removed and a flexible ureteroscope (Table 2) was passed over the 
guide wire into the ureter under fluoroscopic guidance. The guide wire was removed. 
The proximal ureter and the entire collecting system were inspected. Any suspicious 
lesion was biopsied with forceps and ablated.  
Our technique has been evolved over 28-years, and the transition is summarized 
(Table 2). Flexible or semi rigid ureteroscopic therapy was performed with either 2/3 Fr 
electrocautery (100W) or Nd/Ho: YAG laser energy, removing all signs of visible tumor. 
At the end of the procedure, a single-J stent (6 Fr in diameter, external stent) or double-J 
stent (6 Fr in diameter) was placed for several days or until the next ureteroscopy, 
respectively, in cases that required ureteral dilation, ureteral access sheath, and/or 
ablation. Concurrent bladder tumors were treated with standard therapies. Bacillus 
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Calmette-Guerin therapy (BCG) for UTUC was used selectively in cases with positive 
cytology and frequent recurrence of UTUC. BCG (240 mg in normal saline [120 mL] at 
1 mL/min for 2 hours) was administered weekly for a total of six times via a 
percutaneous suprapubic single-J stent placed in the renal pelvis. Suprapubic single-J 
stent is capped between instillations and kept during administration period, which is 
usually 6 weeks. 
 
2.2.  Follow-up 
Ureteroscopy was generally conducted every 3 months with cystoscopy and urine 
cytologic analysis for at least the first 2 years. Additional ureteroscopy and cystoscopy 
were performed at 6-month intervals for the first 3 to 5 years. Then, these procedures 
were continued at 6-month intervals thereafter for up to 10 years. Whenever tumors 
recurred, the follow-up schedule was reset to the initial intervals. Evaluations of 
additional upper tract tumors or metastasis were conducted at 6-month intervals for the 
first 5 years, and at 12-month intervals for the next 5 years, by retrograde 
ureteropyelography intravenous urogram or CT urography depending on renal function. 
Intravenous urogram or CT urography was avoided when retrograde ureteropyelography 




2.3.  Statistical analysis 
The Kaplan-Meier method was used to estimate survival data, including overall survival 
(OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and 
nephron-sparing survival (NSS). Tumor recurrence was defined as ipsilateral or 
contralateral upper tract recurrence determined ureteroscopically or radiologically, or 
the appearance of metastasis. CSS was determined when deaths could be directly 
attributed to UTUC by registry data and a review of clinical case notes. Statistical 
analyses were performed using EZR version 1.36 (Saitama Medical Center, Jichi 





3.1.  Patient demographics and tumor characteristics  
From January 1991 to April 2011, 15 patients were newly managed with ureteroscopy 
for UTUC. The mean follow-up for all patients was 143 months (11.9 years), with a 
median follow-up of 140 months (11.7 years; range, 27-251 months [2.3-20.9 years]). 
All patients were followed up for >6 years, except for one who died of UTUC at 4.9 
years, and one who died of lung cancer at 2.2 years, after initial ureteroscopic 
management. 
The patient demographics are listed, and the detailed ureteroscopic procedures for 
each patient are illustrated in a swimmer survival plot (Table 3) (Figure 1). The patient 
anesthetic fitness was generally classified according to American Society of 
Anesthesiologists (ASA) grade; only 1 patient was classified as ASA grade 3 (patient 
No. 13). Two patients underwent neither transurethral bladder tumor resection (TUR-Bt) 
nor nephroureterectomy before initial ureteroscopic management (patient No. 1 and 3), 
and 8 patients had been previously treated with nephroureterectomy, resulting in a 
solitary kidney (53%). Five patients (33%) were indicated as elective cases, including 
those with small, low-grade UTUC. 
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Fifty-three percent of tumors were in the renal pelvis, while 47 percent were in the 
ureter (Table 4). One patient had a tumor >2.0 cm in diameter (2.1 cm) that was over the 
limit of our indication for ureteroscopic management; nevertheless, ureteroscopic 
management was chosen because the patient had previously undergone 
nephroureterectomy and strongly wished to spare his solitary kidney to avoid aneuric 
dialysis (patient No. 12). One case had bilateral tumors managed with ureteroscopy; the 
left tumor was Ta (G2) and was treated ureteroscopically, while the right tumor was Tis 
(G3) and was treated with upper tract BCG (patient No. 14). 
 
3.2.  Procedure outcomes 
During the follow-up period, 15 patients underwent a total of 268 (range, 5 to 35 per 
patient) ureteroscopy procedures and 66 (range, 1 to 11 per patient) laser ablation 
therapy procedures. Of the 268 procedures, two postoperative complications (1%) 
occurred, both of which were pyelonephritis. No patients developed ureteral stricture. 
Evaluation was not completed in one procedure because the ureteroscope could not pass 
a torturous ureter; a ureteral stent was placed and a second procedure was performed 
successfully 1 month later (patient No. 12).  
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Three patients underwent nephroureterectomy due to the recurrence which was not 
managed by ureteroscopy (patient No 5, 12 and 13). After nephroureterectomy, no 
recurrences were observed; however, 1 patient proceeded to hemodialysis due to loss of 
bilateral kidneys (patient No. 12); this was the only case in the cohort that required 
dialysis. Note this is the patient who had an initial tumor size of 2.1 cm, which is 
outside the indication, as previously described. He received two courses of neoadjuvant 
gemcitabine, cisplatin, and paclitaxel (GCP) combination chemotherapy, and the tumor 
decreased from 2.1 cm to 1.3 cm. Then, laser ablation was performed, followed by one 
additional course of GCP chemotherapy. The recurrent tumor was too extensive to be 
managed ureteroscopically; thus, the patient underwent right nephroureterectomy and 
initiated dialysis. Two cases received chemotherapy, including this case. The other case 
received tegafur-uracil for lymph node metastasis (patient No 14), and died of UTUC 
4.9 years after initial ureteroscopy. 
BCG perfusion therapy for UTUC was performed in 7 patients (patient No. 1, 3, 6, 8, 
11, 14, and 15) (Figure 1). The purpose of BCG was prevention of recurrence of UTUC 
in 6 patients (patient No. 1, 3, 6, 8, 11, and 15) and treatment of CIS in the contralateral 
side in 1 patient (left side of patient No. 14). Of these, 4 patients did not experience 




3.3. Survival outcomes 
Overall, 8 (53%) patients died during a mean follow-up of 11.7 years. Only 1 patient 
(7%) experienced cancer-specific mortality, as described previously. The other causes of 
death were lung cancer (2/15 [14%]), pneumonia (2/15 [14%]), prostate cancer (1/15 
[7%]), small intestine perforation from ileus (1/15 [7%]), and aging at 85 years (1/15 
[7%]). In Kaplan-Meier estimates of survival outcomes, the estimated CSS rates were 
93% at 5, 10, 15, and 20 years, respectively (Table 5) (Figure 2). The estimated OS 
rates were 86%, 80%, 54%, and 20% at 5, 10, 15, and 20 years, respectively. The 
estimated mean and median OS were 14.5 and 16.6 years, respectively, while the 
estimated median CSS time was not reached. A total of 54 upper tract recurrences were 
experienced over a mean follow-up of 11.0 years, with an incidence of 3.6 per patient 
for the entire cohort. The location of recurrences is described in Table 6. Two patients 
did not experience recurrence after initial ureteroscopic ablation (patient No. 3 and 4). 
Estimated RFS was 13% at 5 years, and median RFS was 12 months. The estimated 
NSS was 79% at 5 years and the median NSS time was not reached. Eight patients 
developed 26 bladder recurrences after initial UTUC, and TUR-Bt was performed along 





The present study illustrates the natural history of UTUC patients undergoing 
ureteroscopic management. This study has the longest follow-up duration (mean, 11.9 
years) accompanied by complete and detailed descriptions of each patient course 
compared to previous studies (Table 1) [6-9]. During nearly 12 years of follow-up, only 
1 patient experienced disease-specific mortality. The present results provide further 
reassurance to both clinicians and patients regarding the safety of ureteroscopic 
management as a treatment option for select patients with UTUC. 
Endoscopic management of UTUC has generally been limited to solitary low-grade 
disease in high-risk patients. However, in recent years, the indications for this type of 
management have begun to be applied in carefully selected patients with a normal 
contralateral kidney [1]. Even in the present study, 5 (33%) patients electively 
underwent ureteroscopic management. Among these patients, survival outcomes 
compared to nephroureterectomy are the biggest concern. The UTUC Collaborative 
reported the outcomes of 1363 patients who underwent nephroureterectomy, with 5-year 
CSS rates of 93.5% for patients with pT0/Ta/Tis disease and 91.0% for patients with 
pT1 disease, and 10-year CSS rates of 89.6% for patients with pT0/Ta/Tis disease and 
85.4% for patients with pT1 disease [16]. The estimated CSS rates in the present series 
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compared favorably, with 5-, 10-, and 20-year CSS rates of 93% overall. These survival 
outcomes are comparable to those reported for similar patients in the literature (Table 5). 
However, 15- and 20-year CSS rates are lacking in other studies. Our long observation 
period provides new and excellent information, leading to further support of this 
indication [8, 17]. 
OS was also favorable in the present study, with estimated 5- , 10-, 15- , and 20-year 
OS rates of 86%, 80%, 54%, and 20%, respectively. In previous studies of ureteroscopic 
management, estimated 5-year OS rates of 57-75% and 10-year OS rates of 40-56% 
have been reported [4, 8, 18]. No previous studies have provided 15- or 20-year OS data. 
The patient backgrounds in the present study were comparable to those in previous 
studies (Table 1). The observed favorable OS might have been influenced by favorable 
CSS. The 20-year OS rate of 20% appears to be relatively low. However, considering 
that the mean age at diagnosis is 66 years and more than half of the present patients had 
a solitary kidney, favorable OS is expected. The average Japanese life span is 84 years. 
High CSS and low long-term OS is characteristic of cancers of low malignant potential, 
such as low-risk prostate cancer, in which radical prostatectomy is not always the best 
management option [19]. The present results suggest that ureteroscopic management of 
UTUC is a reasonable option in select patients compared to nephroureterectomy. Our 
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favorable outcomes seem to be associated with high adherence of our patients to strict 
follow-up protocol. We conducted ureteroscopic management for only patients who 
consent the frequent ureteroscopy instead of preserving renal function. 
Despite the favorable survival outcomes observed herein, ureteroscopic treatment is 
associated with a high overall upper tract recurrence rate of 87%, with 5- and 10-year 
RFS rates of 13% and 13%, respectively. These low RFS rates also emphasize the 
importance of strict follow-up and patient compliance as a requirement for successful 
endoscopic management. Despite the high upper tract recurrence rate, 2 patients who 
electively underwent ureteroscopic management had no recurrences and avoided 
unnecessary nephroureterectomy. In addition, the NSS was 79% at 5, 10, and 20 years. 
These data suggest that ureteroscopic management can yield a high long-term 
nephron-sparing rate despite a high rate of upper tract recurrence in select patients.  
Preventing unnecessary nephroureterectomy reduces the risk of complications 
associated with surgery or chronic renal failure, especially in cases with a solitary 
kidney. Ureteroscopic management is associated with fewer complications than 
nephroureterectomy [20]. In addition, we previously reported that lower renal function 
due to a solitary kidney influences the risk of cardiovascular events [21]. It has been 
well documented that once placed on dialysis, elderly patients have limited survival, 
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even in Japan. The survival rates of dialysis patients in 2012 were 73% at 3 years and 
60% at 5 years; [22] the 5-year survival rate was worse in elderly patients at 27% [22, 
23]. 
Fifty-three percent of patients in the present study developed intravesical recurrence, 
which is similar to the percentages in other ureteroscopic reports [6, 7, 17]. However, all 
intravesical recurrences were noninvasive papillary tumors, and were resected 
endoscopically without total cystectomy. 
BCG is currently the most common drug for upper urinary tract perfusion; however, 
its utility is still regarded as investigational because of the small sample size of most 
previous studies [1, 24, 25]. A report with the largest experience showed no significant 
benefit associated with adjuvant BCG perfusion after ablation or percutaneous resection 
of UTUC [26]. However, BCG perfusion therapy for UTUC was effective in the present 
study: 4 of 6 patients (67%) with G2 UTUC did not experience upper tract recurrence 
after BCG. The role of BCG perfusion after ablation of Ta/T1 tumors is not as apparent, 
and should be evaluated on an individual basis. 
Almost all procedures were performed in the present study without complications. A 
major complication of ureteroscopic treatment is ureteric stricture, which occurs in 3% 
to 23% of patients; fortunately, no patients in the present study developed stricture [7, 
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17, 27]. In general, stricture is treated by stenting, balloon dilatation, or laser incision; 
however, rare cases require nephroureterectomy [28]. Additional concerns include 
undergrading and the overlooking of UTUC lesions. One study reported that lesions 
were missed in up to 25% of patients, and nearly 50% of carcinoma in situ lesions were 
missed [28]. Therefore, intensive endoscopic surveillance is critical during follow-up. 
The performance of endoscopes has been continuously developed over the year. The 
introduction of new imaging including NBI with Olympus🄬🄬, SPIES with Storz🄬🄬 might 
help decrease the frequency of URS and recurrences. The introduction of UroVysion 
fluorescence in situ hybridization can also improve the diagnostic accuracy of UTUC 
[29]. Furthermore, photodynamic diagnosis using 5-Aminolevulinic Acid might be 
helpful for diagnosis and ablation also in UTUC in the future [30]. As newly alternative 
kidney-sparing treatment, primary chemoablation using instillation of UGN-101, a 
mitomycin-containing gel for low-grade UTUC might offer the disease eradication [31]. 
Limitations of this study include its retrospective nature and selection bias, and as 
with most other UTUC endoscopic management series, the study had a very small 
sample size and was conducted at a single center. The incidence of non-invasive UTUC 
is extremely rare; therefore, multicenter studies are required to elucidate survival 
efficacy of nephron-sparing management. Nonetheless, the very long duration of 
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follow-up of this study, which is double that of previous studies, makes our data unique 
and strong among published studies. Another limitation is very long enrollment period. 
Most of our procedures were done with electrocautery, however today, Holmium or 
Neodynium laser is commonly used for this indication due to tremendous advances in 
technology. These laser treatments are known more effective and safer [32]. In our 
institution, laser ablation was introduced in 2014, and even better results are expected. 
 
5. Conclusions 
The present study provides information regarding the natural history of UTUC 
patients treated with ureteroscopic management. Although survival outcomes with a 
mean follow-up of 12 years were excellent, upper tract recurrence was common. Thus, 
under strict surveillance, we advocate the use of ureteroscopic management for properly 
selected patients with UTUC. 
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Figure 1. Swimmer survival plot for subjects who underwent ureteroscopic 
management. No patient who had T1 (dark green) disease died of upper tract urothelial 
carcinoma (UTUC). The only case who died of UTUC (No. 14) had bilateral tumors: 
left tumor was Ta (G2), which was treated ureteropscopic ablatoin, while the right 
tumor was Tis (G3), which was treated with upper tract BCG.  




Table 1. Ureteroscopic treatment of upper tract urothelial carcinoma; long-term 
follow-up. 










  Follow-up, 
months, mean 
63 52 73 44.3 143 
  No. of patients 73 66 10 80 15 
  Average age, years 68 73 69 73 66 
  Male, % 62 53 70 65 80 
  Local 
recurrence, % 
68 77 50 91 87 
  Progression, % 19  15 0 32 7 
  Stricture, % 16 N/A N/A N/A 0 





Table 2. The changes of ureteroscopic techniques. 
 
Ⅰ Ⅱ Ⅲ 
 















(+) (+) (-) (-) (-) 
Peel-away 
sheath 





URF AUR-9 Multi-scope Multi-scope Multi-scope 






AUR-9 (8.5, 2.5Fr) ↓ ↓ ↓ 
(9.8, 3.6Fr)  AUR-9,8 AUR-7 URF-P5 
   (7.2, 3.6Fr) (5.3F, 3.6F) 
   URF-P3 URF-P6 
   (6.9, 3.6Fr) (4.9F, 3.6F) 
    URF-V2 
    (8.5F, 3.6F) 
Access sheath (-) (-) (-) (-) 
Flexor® (12-14Fr)  
or 
     Navigator® (11/13Fr) 
Control of the 












Electric Electric Electric Electric Laser 
Laser devise     VersaPulse®SelectTM 
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     (Ho: YAG 80W/ 
Nd: YAG 100W) 
Intensity and 
laser pulses 
30W 30W 30W 30W 
Ho: YAG laser for 
ablation 
(0.5-0.6J, 5-10Hz) 
     or 
     







Table 3. Patient characteristics. 
  
N=15 
Median age, years (IQR)  64 (60-72) 
Sex, n (%) Male 12 (80) 
   Female 3 (20) 
ASA score, n (%) 1 7 (47) 
   2 7 (47) 
   3 1 (7) 
Reason for URS, n (%) Solitary kidney 8 (53) 
   Compromised renal function 1 (7) 
   Poor general condition 1 (7) 
   Elective 5 (33) 
Previous UC, n (%) None 2 (13) 
   TUR-Bt 7 (47) 
   Nephroureterectomy 8 (53) 
ASA, American Society of Anesthesiologists; IQR, interquartile range; TUR-Bt, 













Initial cytology Negative 12 (80) 7 (70) 5 (100) 
 Positive 3 (20) 3 (30) 0 (0) 
Primary tumor Renal pelvis 8 (53) 7 (70) 1 (20) 
        Ureter 7 (43) 3 (30) 4 (80) 




0.5 (0.2-2.3) 0.6 (0.2-2.3) 0.5 (0.2-2.0) 
 <1.0 10 (67) 6 (60) 4 (80) 
 1.0-1.5 2 (13) 2 (20) 0 (0) 
 1.5-2.0 2 (13) 1 (10) 1 (20) 
 >2.0 1 (7) 1 (10) 0 (0) 
Tumor grade G1 1 (7) 1 (10) 0 (0) 
 G2 12 (80) 8 (80) 4 (80) 
 G2+3* 1 (7) 1 (10) 0 (0) 




11 (73) 7 (70) 4 (80) 
 T1 3 (20) 2 (20) 1 (20) 
        Ta+Tis** 1 (7) 1 (10) 0 (0) 
*Bilateral case: the left-side lesion was G2, and the right-side lesion was a G3 
carcinoma in situ. 




Table 5. Survival outcomes for ureteroscopic treatment of upper tract urothelial 
carcinoma; long-term follow-up. 
  Studies 





















Cutress et al7 (All 
cases) 
N/A 89 77 N/A N/A  N/A 70 40 N/A N/A 
Grasso 
et al8 
Low-grade 97 87 78 N/A N/A  93 74 56 N/A N/A 
 High-grade 54 0 0 N/A N/A  54 0 0 N/A N/A 
Reusuger et al9 (All 
cases) 
100 100 100 N/A N/A  N/A N/A N/A N/A N/A 
Scotland et al9 (All 
cases)* 
N/A 84 65 N/A N/A  N/A 75 39 N/A N/A 
Current study (All 
cases) 
100 93 93 93 93  100 86 80 54 20 
*All patients had at least one lesion larger than 2 cm in their cohort. 
